tirzepatide sweden approved for obesity by the FDA – to be branded as Zepbound Welcome to Mounjaro® (tirzepatide injection)
Description
White paper AGA: POWERpractice guide on obesity and weight management, education, and resources
Retatrutide is being studied as a triple-receptor medication that targets GIP, GLP-1, and glucagon receptors
[12] Adverse effects [edit] Preclinical, phase I, and phase II clinical trials indicated that tirzepatide exhibits adverse effects similar to those of other established GLP-1 receptor agonists, such as dulaglutide (sold as Trulicity) and semaglutide (sold as Wegovy, Ozempic, and Rybelsus)
do not use if you have a history of severe gastrointestinal disease Signs of low blood sugar, for example: dizziness, weakness, shakiness, jitteriness, headache, anxiety/mood changes, rapid heartbeat, confusion, slurred speech, sweating, or lightheadedness
Maybe years
Long-term dosing considerations Both compounds are intended for long-term use
